The firm is pleased to distribute the Q1 2025 edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the...more
The firm is pleased to distribute the Q2 2024 edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the...more
9/25/2024
/ Algorithms ,
Artificial Intelligence ,
Copyright Office ,
EU ,
FCC ,
Federal Trade Commission (FTC) ,
Innovative Technology ,
Machine Learning ,
NIST ,
Securities and Exchange Commission (SEC) ,
Technology Sector ,
USPTO
The firm is pleased to distribute the Q1 2024 edition of All Eyes on AI: Regulatory, Litigation, and Transactional Developments, which closely follows the evolving regulatory landscape for artificial intelligence (AI) in the...more
5/24/2024
/ Antitrust Division ,
Artificial Intelligence ,
Biden Administration ,
Canada ,
EU ,
Executive Orders ,
FCC ,
Federal Trade Commission (FTC) ,
Financial Services Industry ,
New Legislation ,
Securities and Exchange Commission (SEC) ,
Technology Sector ,
U.S. Treasury ,
USPTO
Wilson Sonsini’s 31st Annual Medical Device & Digital Health Conference will address topics of critical importance to medical device and digital health companies, including early and late-stage venture financing, partnering...more
5/15/2024
/ Acquisitions ,
Artificial Intelligence ,
Best Practices ,
Business Strategies ,
Business Valuations ,
Compensation ,
Data Privacy ,
Digital Health ,
Early Stage Companies ,
Events ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Technology ,
Innovation ,
Investment Management ,
Investment Opportunities ,
Investment Portfolios ,
Investors ,
Life Sciences ,
Med Tech ,
Medical Devices ,
Mergers ,
Reimbursements ,
Startups ,
Strategic Partnerships ,
Venture Capital
The U.S. patent system is based upon a quid pro quo balance that incentivizes innovation via a time-limited patent exclusivity, while encouraging the dissemination of new ideas for public benefit and use upon expiration of...more
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences...more